JPMorgan downgrades CompoSecure stock to Underweight on valuation concerns

JPMorgan downgraded CompoSecure (CMPO) to Underweight with a $16 price target, citing valuation concerns as the stock trades at 11x next-twelve-months adjusted EBITDA, implying it's "priced to perfection." The firm also noted "choppy growth" and declining Street adjusted EBITDA estimates for 2026/2027, despite CMPO's recent strong stock performance and a Q2 2025 revenue beat that contrasted with a significant earnings per share miss.

Analysis

JPMorgan's downgrade of CompoSecure (CMPO) to Underweight with a $16.00 price target introduces a significant element of caution following the stock's powerful rally of 89.5% over the past year. The primary driver for the downgrade is valuation, with the stock trading at 11x next-twelve-months adjusted EBITDA, a level JPMorgan describes as "priced to perfection" and near all-time highs. This valuation concern is compounded by what the firm calls "choppy growth" and "limited visibility" into the company's back-half loaded guidance. Further supporting this cautious outlook, Street adjusted EBITDA estimates for 2026 and 2027 have declined by 5% and 10%, respectively. This bearish view from a major institution directly conflicts with the company's recent operational results and market momentum. CompoSecure's second-quarter 2025 earnings report presented a mixed picture, featuring a significant revenue beat of 8.11% and a return to 10% double-digit growth, yet simultaneously posting a substantial earnings per share miss of -$0.07 against a $0.21 consensus. The situation is further complicated by the fact that four other analysts have recently revised their earnings estimates upward, creating a clear divergence of opinion in the market.

Key Decisions for Investors

• Investors should critically assess the current valuation at 11x NTM adjusted EBITDA, as JPMorgan's downgrade suggests the stock is 'priced to perfection' and may be vulnerable to a correction following its 89.5% year-long rally.
• Closely monitor upcoming quarterly reports for progress against the company's back-half loaded guidance, as execution will be critical to validating the current share price and refuting concerns over growth visibility.
• Investigate the drivers behind the significant Q2 divergence between the strong revenue beat and the substantial EPS miss (-$0.07 vs $0.21 estimate) to better understand the company's true profitability and operational leverage.
• Consider the declining Street adjusted EBITDA estimates for 2026 and 2027 as a key forward-looking risk indicator that may signal longer-term margin or growth challenges.